ACQUISITION (Details 4) (Eclat Pharmaceuticals [Member], USD $) In Thousands, unless otherwise specified	6 Months Ended
Jun. 30, 2012	Jun. 30, 2011
Eclat Pharmaceuticals [Member]
Revenues	$ 13,605	$ 13,532
Net Income/(Loss)	$ (6,430)	$ (10,549)

The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Name:	us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration